Buzzing Stocks: Durata Therapeutics Inc (NASDAQ:DRTX), Unilife Corporation (NASDAQ:UNIS), LipoScience Inc (NASDAQ:LPDX)

Boston, MA 10/07/2014 (wallstreetpr) – As a follow up action to the recent announcement by drug maker Durata Therapeutics Inc (NASDAQ:DRTX) that it has agreed to be bought out by drug major Actavis plc (NYSE:ACT) for sale price of $675 million, The Rosen Law Firm, P.A. announced on 6th October that it is launching investigations […]

The Market Outlook: Durata Therapeutics (DRTX), Unilife Corp (UNIS), Revolution Lighting Technologies (RVLT)

Boston, MA 10/06/2014 (wallstreetpr) – Durata Therapeutics Inc (NASDAQ:DRTX) has agreed to be purchased by Actavis plc (NYSE:ACT). The deal is expected to complete later this year or early next year. DRTX has been offered $23 per share, which suggests 66% premium from the previous closing price before the deal was made public. The companies said […]

Shareholder Alert: Ingredion Inc (NYSE:INGR), Nautilus, Inc. (NYSE:NLS), Durata Therapeutics Inc (NASDAQ:DRTX)

Boston, MA 05/16/2014 (wallstreetpr) – Ingredion Inc (NYSE:INGR) launched an online calculator to help confectionery manufacturers to see how they can make big financial savings by using its new starch ingredient called PERFECTAGEL MPT. The company is offering the ingredient as a replacement for gelatin. Confectionary manufacturing market can save up to $0.5 million per […]

What’s Latest With Durata Therapeutics Inc (NASDAQ:DRTX); WSP Holdings Limited (ADR) (NYSE:WH) And SmartPros Ltd. (NASDAQ:SPRO)?

Boston, MA 03/20/2014 (wallstreetpr) – Durata Therapeutics Inc (NASDAQ:DRTX)‘s lead product dalbavancin can become an important catalyst for the company as it is up for approval from the FDA. It is to be noted that Durata acquired the rights of dalbavancin from its previous owner, Pfizer, who did not proceed with the new requirement of […]